Lemonex signs MOU with WHO mRNA vaccines tech hub

Its drug delivery system DegradaBALL enables room-temperature storage, facilitating distribution in developing countries

Lemonex signs MOU with WHO mRNA vaccines tech hub
Jeong-Min Nam 1
2023-05-09 18:24:42 peux@hankyung.com
Bio & Pharma

South Korea's gene therapeutics developer Lemonex announced on Tuesday that it has signed a memorandum of understanding (MOU) with the World Health Organization (WHO) to manufacture messenger RNA (mRNA) vaccines utilizing its proprietary drug delivery system (DDS), DegradaBALL.

The pharmaceutical company will provide DegradaBALL to the WHO mRNA technology transfer hubs located in Cape Town, South Africa. Conventional mRNA vaccines require storage and transport at temperatures between -20 and -80 degrees Celsius, posing significant challenges for distribution in developing countries.

According to Lemonex, DegradaBALL addresses this issue by allowing vaccines to be stored at room temperature for over two years.

Composed primarily of silicon dioxide (SiO2), DegradaBALL is a three-dimensional nanoparticle featuring a hollow, golf ball-like structure with holes on its surface.

"The drug can be placed between the holes and freeze-dried, enabling distribution even to countries with vast distances and high temperatures," a Lemonex official said. "This technology also allows for advanced production, inventory storage and distribution."

Currently, lipid nanoparticles and adeno-associated viruses are the most widely utilized gene therapy drug delivery systems, as seen in Moderna and Pfizer's COVID-19 vaccines. However, these systems have limitations, including side effects such as blood clots and the inability for repeated administration. DegradaBALL, on the other hand, lacks these drawbacks, making it an ideal candidate for vaccine development, according to Lemonex.

Write to Jeong-Min Nam at peux@hankyung.com
#Lemonex #WHO #mRNA vaccines #WHO mRNA technology transfer hubs #drug delivery system #DegradaBALL #Moderna #Pfizer #COVID-19

SK Bioscience to produce MSD’s new Ebola vaccine candidate

SK Bioscience to produce MSD’s new Ebola vaccine candidate

SK Bioscience Co., the drug-making unit of South Korea’s SK Group, announced on Monday that it has signed a contract with MSD, a global pharmaceutical company based in the United States, to start consignment production of next-generation Zaire Ebola vaccine candidate.MSD is currently dev

GC Biopharma wins $44 mn flu vaccine order from WHO agency

GC Biopharma wins $44 mn flu vaccine order from WHO agency

South Korea's pharmaceutical firm GC Biopharma Co. said on Monday that it has won a $44.3 million (57.9 billion won) order for flu vaccines in a drug tender offered by the Pan American Health Organization (PAHO), an arm of the World Health Organization (WHO).Accordingly, GC's flu vaccine will

Sanofi, Korean biotech Lemonex ink material transfer agreement

Sanofi, Korean biotech Lemonex ink material transfer agreement

Lemonex CEO Won Cheol-hee South Korean biotech Lemonex Inc. has signed a material transfer agreement (MTA) with global pharmaceutical giant Sanofi S.A. to use the Korean biotech’s drug delivery platform technologies, Lemonex said on Tuesday.  The platform, named DegradaBALL, e

SK Bioscience becomes first to win domestic COVID-19 vaccine contract 

SK Bioscience becomes first to win domestic COVID-19 vaccine contract 

SK Bioscience facility in North Gyeongsang Province SK Bioscience Co. said it reached a deal with Korea’s disease control agency to supply 10 million doses of the country’s first experimental COVID-19 vaccine.This is the first time a vaccine developed by a South Korean company has s
(* comment hide *}